Heching Moshe, Cohen-Kutner Moshe, Ben-Zvi Haim, Slomianksy Liora, Chass Maurice Elital, Nur Maymon Noa, Mandel Shira, Oholy Michal, Moses Rony, Lavon Michal, Kaufman Katherine, Mayost Lev-Ari Orel, Shachar Tamar, Weinberg Joel, Kramer Mordechai R, Bachnoff Niv
Pulmonology Institute and Adult CF Center, Rabin Medical Center, Beilinson Hospital, 39 Jabotinsky Street, Petach Tikva 4941492, Israel.
School of Medicine, Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv 6997801, Israel.
J Clin Med. 2025 Jul 23;14(15):5208. doi: 10.3390/jcm14155208.
People with cystic fibrosis (pwCF) frequently suffer from chronic lung infections, with being the predominant pathogen contributing to disease progression and morbidity. The increasing prevalence of multi-drug-resistant (MDR) has diminished treatment options. Antimicrobial peptides (AMPs) have emerged as promising alternatives to conventional antibiotics due to their unique membrane-targeting mechanisms. OMN51, a novel bioengineered AMP derived from capitellacin, was evaluated for antimicrobial activity against in sputum samples from pwCF. This study aimed to compare the bactericidal effects of OMN51 with those of a range of conventional antibiotics known to have activity against clinical isolates derived from pwCF. clinical isolates were obtained from fifty-six unique sputum cultures of pwCF at a tertiary-university-affiliated hospital. Minimum inhibitory concentrations (MICs) of OMN51 and comparator antibiotics were determined using broth microdilution. Antimicrobial susceptibility was evaluated using the Kirby-Bauer disc diffusion method. OMN51 demonstrated in vitro bactericidal activity across all isolates, including MDR strains. MIC values for OMN51 ranged from 4 to 16 µg/mL, with no observed resistance or cross-resistance. Comparative analysis revealed the superior efficacy of OMN51 compared with conventional antibiotics. OMN51 exhibits robust in vitro activity against MDR , supporting its candidacy as a therapeutic agent for MDR associated infections. Further studies are warranted to assess pharmacokinetics and in vivo safety and efficacy. OMN51 represents a first-in-class, membrane-targeting therapeutic showing promise against MDR .
囊性纤维化患者（pwCF）经常遭受慢性肺部感染， 是导致疾病进展和发病的主要病原体。多重耐药（MDR） 的患病率不断上升，减少了治疗选择。抗菌肽（AMPs）由于其独特的膜靶向机制，已成为传统抗生素的有希望的替代品。OMN51是一种源自capitellacin的新型生物工程抗菌肽，对pwCF痰液样本中的 进行了抗菌活性评估。本研究旨在比较OMN51与一系列已知对源自pwCF的临床分离株有活性的传统抗生素的杀菌效果。临床分离株取自一家大学附属医院的56例独特的pwCF痰液培养物。使用肉汤微量稀释法测定OMN51和对照抗生素的最低抑菌浓度（MICs）。使用 Kirby-Bauer 纸片扩散法评估抗菌药敏性。OMN51在所有 分离株中均表现出体外杀菌活性，包括MDR菌株。OMN51的MIC值范围为4至16µg/mL，未观察到耐药性或交叉耐药性。比较分析显示OMN51与传统抗生素相比具有更高的疗效。OMN51对MDR 表现出强大的体外活性，支持其作为MDR 相关感染治疗药物的候选资格。有必要进一步研究以评估其药代动力学以及体内安全性和疗效。OMN51是一流的膜靶向治疗药物，对MDR 显示出前景。
